SGLT2 Inhibitors: Alternatives or Complementary Therapeutic Options | Abstract

➣ Special Issue: Editorial

➣ Diab Res Open Access. 2020 Feb 08;2(S1):15-16

Alkhatib J1,2*

1Department of Legal Medicine, Toxicology of Forensic Science and Toxicology, School of Medicine, Jordan University of Science and Technology, Jordan

2International Mariinskaya Academy, department of medicine and critical care, department of philosophy, Academician secretary of department of Sociology

Corresponding Author: Ahed J Alkhatib

Address: Department of Legal Medicine, Toxicology of Forensic Science and Toxicology, School of Medicine, Jordan University of Science and Technology, Jordan; Tel: 00962795905145; E-mail: ahed.alkhatib64@yahoo.com, ajalkhatib@just.edu.jo, drahedalkhatib@yahoo.com

Received date: 26 January 2020; Accepted date: 01 February 2020; Published date: 08 February 2020

Diabetes type 2 is a real challenge of health across the world. Therapeutic options are varied and include various lines such as starting with giving metformin with increasing doses and ending with insulin at increasing dose model.

I think that a science philosophical problem has been involved in the research and science of diabetes. The definition of diabetes depends mainly on determining insulin level or function. But insulin level is not measured as a direct cause of diabetes, while the glucose level is measured as a result of diabetes (indirect proof). The perceived idea of diabetic cause is insulin deficiency as either in concentration or function. A functional insufficiency of the pancreas was the focus point of view which requires giving insulin treatment as diabetes progresses.

Citation: Alkhatib J. SGLT2 Inhibitors: Alternatives or Complementary Therapeutic Options. Diab Res Open Access. 2020 Feb 08;2(S1):15-16.

Copyright © 2020 Alkhatib J. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Keywords: SGLT2 Inhibitors; Diabetes; Pancreas

Facebooktwitterlinkedininstagramflickrfoursquaremail

asploro

Asploro Open Access Publications Limited